SCHEMBL5537342

SCHEMBL5537342

[CH2]CCCCc1nc2ccccc2s1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.60
ALOX15 P16050 1/20 0.60
HTT P42858 1/20 0.60
DRD2 P14416 6/20 0.58
HTR1A P08908 6/20 0.58
HTR7 P34969 6/20 0.58
SLC6A4 P31645 3/20 0.58
UBE2T Q9NPD8 1/20 0.56
ASIC3 Q9UHC3 1/20 0.56
PDE10A Q9Y233 1/20 0.53
LMNA P02545 1/20 0.52
HTR2A P28223 4/20 0.52
HTR2C P28335 3/20 0.52
RAB9A P51151 3/20 0.51
HPGD P15428 2/20 0.51
DRD3 P35462 5/20 0.51
DRD4 P21917 3/20 0.51
POLB P06746 1/20 0.50
ATM Q13315 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543152 0.98 SMN1; SMN2 (0.59) SMN1; SMN2ALOX15HTTDRD2HTR1A
SCHEMBL2047532 0.95 SMN1; SMN2 (0.62) SMN1; SMN2ALOX15HTTDRD2HTR1A
Bromide SCHEMBL11522514 0.87 SMN1; SMN2 (0.66) SMN1; SMN2ALOX15HTTDRD2HTR1A
SCHEMBL8904885 0.87 UBE2T (0.61) SMN1; SMN2ALOX15HTTDRD2HTR1A
SCHEMBL9641726 0.87 SMN1; SMN2 (0.70) SMN1; SMN2ALOX15HTTDRD2HTR1A
SCHEMBL19372016 0.83 UBE2T (0.70) SMN1; SMN2ALOX15HTTDRD2HTR1A
SCHEMBL8088124 0.83 UBE2T (0.66) SMN1; SMN2ALOX15HTTDRD2HTR1A
SCHEMBL22871618 0.83 SMN1; SMN2 (0.60) SMN1; SMN2ALOX15HTTDRD2HTR1A
SCHEMBL175532 0.83 ALOX15 (0.60) SMN1; SMN2ALOX15HTTDRD2HTR1A
SCHEMBL20359904 0.83 SMN1; SMN2 (0.60) SMN1; SMN2ALOX15HTTDRD2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SMN1; SMN2 3985/4885ALOX15 2847/4885HTT 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.